Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 07, 2024 16:01 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
April 30, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List
April 09, 2024 09:15 ET
|
Lily AI
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List.
With Extensive Two-Year Revenue Growth, ValueSelling Associates is Selected to Inc. Magazine’s List of the Pacific Region’s Fastest-Growing Private Companies
February 28, 2024 13:09 ET
|
ValueSelling Associates, Inc.
ValueSelling Associates has been selected to the Inc. 5000 Regionals Pacific list, showcasing the fastest-growing Pacific private companies.
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
February 27, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
January 16, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
- Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive...
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
January 10, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
- ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777...
Fundable for Life, Inc. Partners with The Latino Franchise Association to Provide its Clients TV and Digital Print Media Along with Funding Options
December 21, 2023 08:00 ET
|
Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.
Aclaris Therapeutics Provides Corporate Update
December 19, 2023 16:01 ET
|
Aclaris Therapeutics, Inc.
- ATI-1777 Phase 2a Trial Results Published in JID Innovations -- ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 -- Aclaris Announces Reduction in Workforce - WAYNE, Pa., Dec. 19,...
Fundable for Life, Inc. Partners with Boston BioLife to Provide its Members TV and Digital Print Media Along with Funding Options
December 18, 2023 08:00 ET
|
Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.